SARS-CoV-2 Vaccine (CHO Cell)(Lanzhou Institute of Biological)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSARS-CoV-2 Vaccine (CHO Cell)(Lanzhou Institute of Biological)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Arab EmiratesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNational Vaccine and Serum Institute, ChinaLanzhou Institute Of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Vaccine and Serum Institute, ChinaLanzhou Institute Of Biological Products Co LtdBeijing Institute Of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A